Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug-resistant TB news

Show

From To
Johnson & Johnson announces collaboration between Janssen and USAID to expand access to anti-multidrug-resistant tuberculosis (MDR-TB) compound

Memorandum of Understanding signed to address the global health threat of antibiotic-resistant bacteria.

Published
12 December 2014
From
PR Newswire
Drug-resistant infections could lead to 10 million extra deaths a year – report

The stark figures, published on Thursday, and believed to be the first to quantify the potential impact of antimicrobial resistance (AMR) – drug-resistant infections or superbugs – will be used to make the case to global leaders that urgent action is needed. To put the figures in context there are currently 8.2 million deaths a year from cancer and annual global GDP stands at $70tn to $75tn, with the UK figure around $3tn.

Published
11 December 2014
From
The Guardian
Preliminary Data Show High Success Rate for Dramatically Shortened Multidrug-resistant TB Treatment Option

A nine-month treatment regiment for multidrug-resistant tuberculosis (MDR-TB) appears to be as effective as a 12-month regiment, according to data from two new studies being presented today at the 45th World Conference on Lung Health in Barcelona, Spain.

Published
31 October 2014
From
International Union Against Tuberculosis and Lung Disease
WHO interim guidance on the use of delamanid in the treatment of MDR-TB

A new TB drug with a novel mechanism of action – delamanid - is now available for treatment of adults with multidrug-resistant tuberculosis (MDR-TB). Delamanid was granted conditional approval by the European Medicine Agency in April 2014. Information about this new drug however remains limited, since it has only been through Phase IIb trial and studies for safety and efficacy. WHO is therefore issuing “interim policy guidance” that lists five conditions that must be in place if delamanid is used to treat adults with MDR-TB

Published
29 October 2014
From
World Health Organization
Success short treatment against drug-resistant tuberculosis confirmed

In what has become known as the Bangladesh regimen, ITM’s Armand Van Deun and colleagues developed a treatment of only 9 months. This regimen replaces the currently recommended treatment of 18 to 24 months. In 2010, the researchers reported that this treatment increased the success rate from 65% to 88% for MDR-TB patients in Bangladesh. The treatment is based on a combination of existing drugs.The researchers report a favourable outcome in roughly 85% of cases, in spite of increasing levels of serious second-line drug resistance. A smaller study in Niger confirmed the outstanding results of the shorter treatment.

Published
28 October 2014
From
Institute of Tropical Medicine
UNITAID’s EXPAND-TB and TBXpert MTB-RIF Projects Detect Over A Quarter of all MDR-TB Cases

UNITAID welcomes new data in the World Health Organization’s new global report on tuberculosis (TB) which shows a 30% increase in case detection of multi-drug resistant TB (MDR-TB) in 2013, much of which is attributed to the roll out of the UNITAID-funded EXPAND-TB and TBXpert projects. UNITAID’s EXPAND-TB project enabled the installation of sophisticated testing platform technology in TB reference laboratories across 27 countries, bearing 40% of the MDR-TB burden. This provided the capability to detect MDR-TB for the first time for many countries.

Published
27 October 2014
From
UNITAID
Drug-resistant tuberculosis poses global threat, warn doctors

World Health Organisation says spread of hardier strains of TB across former USSR nations is of ‘critical concern’.

Published
22 October 2014
From
The Guardian
South Africa: Bedaquiline approved to treat multi-drug resistant tuberculosis

The Medicines Control Council has approved Janssen Pharmaceutica's bedaquiline, the first drug specifically designed for treating multi-drug resistant tuberculosis (MDR-TB) to reach the market. Janssen is a subsidiary of Johnson & Johnson.

Published
21 October 2014
From
Business Day
Minsk has extremely high levels of drug-resistant TB, a study in Belarus reveals

Multidrug-resistant (MDR)-TB was found in 35.3% (95% CI 27.7–42.8) of new patients and 76.5% (95% CI 66.1–86.8) of those previously treated. Overall, nearly one in two patients enrolled had MDR-TB. Extensively drug-resistant TB was reported in 15 of the 107 MDR-TB patients (14.0%, 95% CI 7.3–20.7). The findings of this survey in Minsk city are alarming and represent the highest proportions of MDR-TB ever recorded in the world.

Published
29 September 2014
From
TB Europe Coalition
What does new drug PaMZ mean for TB and HIV treatment?

The development of PaMZ has been hailed as a breakthrough. But what do the experts think?

Published
02 September 2014
From
The Guardian
← First12345...15Next →

Filter by country